Boyd SC - Search Results

1

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Carlino MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, Nagrial AM, Scolyer RA, Kefford RF, Long GV, Rizos H. Carlino MS, et al. Among authors: boyd sc. Clin Cancer Res. 2015 Jan 1;21(1):98-105. doi: 10.1158/1078-0432.CCR-14-0759. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370473

2

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H. Lee JH, et al. Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026. Ann Oncol. 2017. PMID: 28327969 Free article.

3

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV. Rizos H, et al. Among authors: boyd sc. Clin Cancer Res. 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24. Clin Cancer Res. 2014. PMID: 24463458

4

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M. Gray ES, et al. Among authors: boyd sc. Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788. Oncotarget. 2015. PMID: 26524482 Free PMC article.

5

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H. Irvine M, et al. Oncogenesis. 2018 Sep 20;7(9):72. doi: 10.1038/s41389-018-0081-3. Oncogenesis. 2018. PMID: 30237495 Free PMC article.

6

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.

Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford RF, Zhang XD, Rizos H. Becker TM, et al. Among authors: boyd sc. Oncogene. 2014 Feb 27;33(9):1158-66. doi: 10.1038/onc.2013.45. Epub 2013 Mar 4. Oncogene. 2014. PMID: 23455323

7

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.

Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, Goding CR, Scolyer RA, Mann GJ, Kefford RF, Rizos H, Becker TM. Boyd SC, et al. J Invest Dermatol. 2013 May;133(5):1269-77. doi: 10.1038/jid.2012.421. Epub 2012 Nov 29. J Invest Dermatol. 2013. PMID: 23190890 Free PMC article.

8

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H. Pupo GM, et al. Among authors: boyd sc. Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017. Biomark Res. 2017. PMID: 28503307 Free PMC article.

9

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, Tseng HY, Jin L, Rizos H, Hersey P, Zhang XD. Croft A, et al. Among authors: boyd sc. J Invest Dermatol. 2014 Feb;134(2):488-497. doi: 10.1038/jid.2013.325. Epub 2013 Aug 6. J Invest Dermatol. 2014. PMID: 23921951 Free article.

10

Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.

Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ; WWARN Vivax Adherence Study Group. Mehdipour P, et al. Malar J. 2023 Oct 10;22(1):306. doi: 10.1186/s12936-023-04725-w. Malar J. 2023. PMID: 37817240 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page